Close Menu

NEW YORK (GenomeWeb) – Invitae reported after the close of the market Tuesday a nearly 14 percent decline in second quarter revenues from the prior year, which was still better than the consensus Wall Street estimate.

For the three months ended June 30, the firm generated $46.2 million in revenues compared to $53.5 million in Q2 2019. The consensus Wall Street estimate was $39.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.